PubRank

Bernd Dörken

Author PubWeight™ 181.72‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 2005 9.16
2 Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003 3.99
3 Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010 2.97
4 Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 2012 2.43
5 Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma. Nat Immunol 2005 2.31
6 Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 2011 2.25
7 Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature. Gynecol Oncol 2005 2.15
8 Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL. Cancer Cell 2012 2.15
9 Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 2009 2.13
10 Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy. J Clin Oncol 2003 2.04
11 Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood 2002 2.03
12 Elevated NF-kappaB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas. Blood 2005 2.00
13 Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. EMBO J 2002 2.00
14 Pathogenesis of non-Hodgkin's lymphoma. J Clin Oncol 2011 1.99
15 Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma. Nat Med 2010 1.93
16 Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol 2011 1.84
17 Opposing roles of NF-κB in anti-cancer treatment outcome unveiled by cross-species investigations. Genes Dev 2011 1.69
18 Synthetic lethal metabolic targeting of cellular senescence in cancer therapy. Nature 2013 1.66
19 Nuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity. J Exp Med 2002 1.66
20 Induction of cell death by the BH3-only Bcl-2 homolog Nbk/Bik is mediated by an entirely Bax-dependent mitochondrial pathway. EMBO J 2003 1.60
21 Cooperative function of CCR7 and lymphotoxin in the formation of a lymphoma-permissive niche within murine secondary lymphoid organs. Blood 2011 1.60
22 IκB-ζ controls the constitutive NF-κB target gene network and survival of ABC DLBCL. Blood 2013 1.55
23 Tumor stroma-derived TGF-beta limits myc-driven lymphomagenesis via Suv39h1-dependent senescence. Cancer Cell 2010 1.53
24 Severe peripheral arterial disease during nilotinib therapy. J Natl Cancer Inst 2011 1.52
25 Malt1-dependent RelB cleavage promotes canonical NF-kappaB activation in lymphocytes and lymphoma cell lines. Proc Natl Acad Sci U S A 2011 1.48
26 Macrophage inflammatory protein 1-alpha (MIP-1 alpha ) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells. Blood 2002 1.46
27 Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 2010 1.46
28 PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A 2013 1.44
29 Gene deregulation and spatial genome reorganization near breakpoints prior to formation of translocations in anaplastic large cell lymphoma. Proc Natl Acad Sci U S A 2009 1.44
30 Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells. Blood 2004 1.43
31 Prognostic value of multimarker analysis in stage III colorectal cancer: one step forward towards an individualized therapy decision. Onkologie 2005 1.42
32 A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein {beta} and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas. Blood 2005 1.42
33 Paclitaxel-induced apoptosis in BJAB cells proceeds via a death receptor-independent, caspases-3/-8-driven mitochondrial amplification loop. Oncogene 2003 1.40
34 Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci U S A 2010 1.40
35 Loss of PU.1 expression is associated with defective immunoglobulin transcription in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease. Blood 2002 1.32
36 The Myc-evoked DNA damage response accounts for treatment resistance in primary lymphomas in vivo. Blood 2007 1.31
37 Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas. Cancer Res 2011 1.30
38 Adenovirus-mediated overexpression of p14(ARF) induces p53 and Bax-independent apoptosis. Oncogene 2002 1.30
39 5-Aza-2'-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia. Int J Cancer 2005 1.28
40 Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study. J Clin Oncol 2005 1.28
41 Ceramide induces mitochondrial activation and apoptosis via a Bax-dependent pathway in human carcinoma cells. Oncogene 2002 1.28
42 Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells. Blood 2004 1.25
43 C/EBPbetaDeltauORF mice--a genetic model for uORF-mediated translational control in mammals. Genes Dev 2010 1.25
44 Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3alpha. Blood 2008 1.25
45 Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3), which promotes viability of Hodgkin/Reed-Sternberg cells. Blood 2005 1.24
46 Cellular senescence in cancer treatment: friend or foe? J Clin Invest 2004 1.23
47 Stroma-mediated dysregulation of myelopoiesis in mice lacking I kappa B alpha. Immunity 2005 1.21
48 Multidomain Bcl-2 homolog Bax but not Bak mediates synergistic induction of apoptosis by TRAIL and 5-FU through the mitochondrial apoptosis pathway. Oncogene 2004 1.20
49 Inactivating I kappa B epsilon mutations in Hodgkin/Reed-Sternberg cells. J Pathol 2003 1.19
50 Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer Chemother Pharmacol 2003 1.19
51 In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway. Blood 2002 1.15
52 Mcl-1 determines the Bax dependency of Nbk/Bik-induced apoptosis. J Cell Biol 2007 1.14
53 C/EBPbeta regulates transcription factors critical for proliferation and survival of multiple myeloma cells. Blood 2009 1.14
54 Clinical cardiac safety profile of nilotinib. Haematologica 2012 1.13
55 c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis. J Exp Med 2004 1.12
56 Differential Emu enhancer activity and expression of BOB.1/OBF.1, Oct2, PU.1, and immunoglobulin in reactive B-cell populations, B-cell non-Hodgkin lymphomas, and Hodgkin lymphomas. J Pathol 2004 1.12
57 Smac induces cytochrome c release and apoptosis independently from Bax/Bcl-x(L) in a strictly caspase-3-dependent manner in human carcinoma cells. Oncogene 2004 1.12
58 Endogenous Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinoma. J Cell Biol 2010 1.11
59 EBAG9 adds a new layer of control on large dense-core vesicle exocytosis via interaction with Snapin. Mol Biol Cell 2005 1.08
60 Immunomodulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesis. Blood 2004 1.07
61 Common clonal origin of an acute B-lymphoblastic leukemia and a Langerhans' cell sarcoma: evidence for hematopoietic plasticity. Haematologica 2010 1.07
62 A modified EBMT risk score and the hematopoietic cell transplantation-specific comorbidity index for pre-transplant risk assessment in adult acute lymphoblastic leukemia. Haematologica 2009 1.05
63 TRAIL sensitizes for ionizing irradiation-induced apoptosis through an entirely Bax-dependent mitochondrial cell death pathway. Oncogene 2005 1.04
64 The apoptosis promoting Bcl-2 homologues Bak and Nbk/Bik overcome drug resistance in Mdr-1-negative and Mdr-1-overexpressing breast cancer cell lines. Oncogene 2002 1.03
65 In vivo expression of survivin and its splice variant survivin-2B: impact on clinical outcome in acute myeloid leukemia. Int J Cancer 2006 1.02
66 The Golgi protein RCAS1 controls cell surface expression of tumor-associated O-linked glycan antigens. J Biol Chem 2003 1.02
67 Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy). BMC Cancer 2008 1.02
68 Notch signaling in leukemias and lymphomas. Curr Mol Med 2008 1.01
69 Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia. Haematologica 2009 1.01
70 Costimulation by CD137/4-1BB inhibits T cell apoptosis and induces Bcl-xL and c-FLIP(short) via phosphatidylinositol 3-kinase and AKT/protein kinase B. Eur J Immunol 2005 1.00
71 Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia. Thyroid 2010 0.99
72 Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia. Eur J Haematol 2002 0.99
73 Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab. Transplantation 2007 0.98
74 Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution. Ann Hematol 2007 0.97
75 Interventionally implanted port catheter systems for hepatic arterial infusion of chemotherapy in patients with colorectal liver metastases: a Phase II-study and historical comparison with the surgical approach. BMC Cancer 2007 0.97
76 Loss of p21 disrupts p14 ARF-induced G1 cell cycle arrest but augments p14 ARF-induced apoptosis in human carcinoma cells. Oncogene 2005 0.97
77 Genomic loss of the putative tumor suppressor gene E2A in human lymphoma. J Exp Med 2011 0.97
78 Does long-term survival in patients with pancreatic cancer really exist? Results from the CONKO-001 study. J Surg Oncol 2013 0.96
79 Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor. Blood Cells Mol Dis 2005 0.93
80 Arsenic trioxide triggers a regulated form of caspase-independent necrotic cell death via the mitochondrial death pathway. Oncogene 2005 0.92
81 A modified EBMT risk score predicts the outcome of patients with acute myeloid leukemia receiving allogeneic stem cell transplants. Eur J Haematol 2011 0.92
82 In vitro susceptibility to dexamethasone- and doxorubicin-induced apoptotic cell death in context of maturation stage, responsiveness to interleukin 7, and early cytoreduction in vivo in childhood T-cell acute lymphoblastic leukemia. Blood 2002 0.91
83 Analysis of p53/BAX in primary colorectal carcinoma: low BAX protein expression is a negative prognostic factor in UICC stage III tumors. Int J Cancer 2002 0.91
84 Cryopreservation of mature monocyte-derived human dendritic cells for vaccination: influence on phenotype and functional properties. Cancer Immunol Immunother 2003 0.90
85 Adenine deoxynucleotides fludarabine and cladribine induce apoptosis in a CD95/Fas receptor, FADD and caspase-8-independent manner by activation of the mitochondrial cell death pathway. Oncogene 2004 0.89
86 Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma. Int J Cancer 2013 0.89
87 Induction of apoptosis by enediyne antibiotic calicheamicin thetaII proceeds through a caspase-mediated mitochondrial amplification loop in an entirely Bax-dependent manner. Oncogene 2003 0.89
88 Assessment of genomic instability in breast cancer and uveal melanoma by random amplified polymorphic DNA analysis. Int J Cancer 2002 0.89
89 Reprogramming of B lymphoid cells in human lymphoma pathogenesis. Cell Cycle 2006 0.89
90 Recurrent chromosomal aberrations in INK4a/ARF defective primary lymphomas predict drug responses in vivo. Oncogene 2005 0.88
91 Utilization of TREC and KREC quantification for the monitoring of early T- and B-cell neogenesis in adult patients after allogeneic hematopoietic stem cell transplantation. J Transl Med 2013 0.88
92 CCL19 (ELC) improves TH1-polarized immune responses and protective immunity in a murine Her2/neu DNA vaccination model. J Gene Med 2012 0.88
93 Tumor necrosis factor alpha sensitizes malignant cells to chemotherapeutic drugs via the mitochondrial apoptosis pathway independently of caspase-8 and NF-kappaB. Oncogene 2004 0.88
94 Second-line therapy in refractory pancreatic cancer. results of a phase II study. Onkologie 2009 0.87
95 p14ARF induces G2 cell cycle arrest in p53- and p21-deficient cells by down-regulating p34cdc2 kinase activity. J Biol Chem 2004 0.87
96 Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib. Hum Immunol 2007 0.87
97 The sorting receptor Sortilin exhibits a dual function in exocytic trafficking of interferon-γ and granzyme A in T cells. Immunity 2012 0.86
98 Filgrastim-induced stem cell mobilization in chronic myeloid leukaemia patients during imatinib therapy: safety, feasibility and evidence for an efficient in vivo purging. Br J Haematol 2004 0.86
99 Multigene analysis of Rb pathway and apoptosis control in esophageal squamous cell carcinoma identifies patients with good prognosis. Int J Cancer 2003 0.86
100 Transcriptional regulation of human survivin by early growth response (Egr)-1 transcription factor. Int J Cancer 2008 0.86
101 Analysis of neuroendocrine differentiation and the p53/BAX pathway in UICC stage III colorectal carcinoma identifies patients with good prognosis. Int J Colorectal Dis 2005 0.85
102 In B-CLL, the codon 72 polymorphic variants of p53 are not related to drug resistance and disease prognosis. BMC Cancer 2005 0.85
103 New insights into the biology of molecular subtypes of diffuse large B-cell lymphoma and Burkitt lymphoma. Best Pract Res Clin Haematol 2012 0.85
104 Peripheral blood sCD3⁻ CD4⁺ T cells: a useful diagnostic tool in angioimmunoblastic T cell lymphoma. Hematol Oncol 2013 0.85
105 Distinction of acute lymphoblastic leukemia from acute myeloid leukemia through microarray-based DNA methylation analysis. Ann Hematol 2004 0.85
106 Reevaluation of the 22-1-1 antibody and its putative antigen, EBAG9/RCAS1, as a tumor marker. BMC Cancer 2005 0.85
107 Genetic dissection of apoptosis and cell cycle control in response of colorectal cancer treated with preoperative radiochemotherapy. BMC Cancer 2006 0.84
108 Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia. Br J Haematol 2007 0.84
109 Epigenetic and genetic analysis of the survivin promoter in acute myeloid leukemia. Leuk Res 2008 0.84
110 Squamous cutaneous epithelial cell carcinoma in two CML patients with progressive disease under imatinib treatment. Eur J Haematol 2003 0.84
111 p14(ARF)-induced apoptosis in p53 protein-deficient cells is mediated by BH3-only protein-independent derepression of Bak protein through down-regulation of Mcl-1 and Bcl-xL proteins. J Biol Chem 2012 0.84
112 The tumor-associated antigen EBAG9 negatively regulates the cytolytic capacity of mouse CD8+ T cells. J Clin Invest 2009 0.84
113 Loss of bHLH transcription factor E2A activity in primary effusion lymphoma confers resistance to apoptosis. Br J Haematol 2007 0.84
114 HER2/neu DNA vaccination by intradermal gene delivery in a mouse tumor model: Gene gun is superior to jet injector in inducing CTL responses and protective immunity. Oncoimmunology 2012 0.84
115 Silencing of APAF-1 in B-CLL results in poor prognosis in the case of concomitant p53 mutation. Int J Cancer 2006 0.83
116 BCR-ABL1(+) acute myeloid leukemia: clonal selection of a BCR-ABL1(-) subclone as a cause of refractory disease with nilotinib treatment. Acta Haematol 2014 0.83
117 Epstein-Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course. Ann Hematol 2006 0.83
118 Value of carbohydrate antigen 19-9 in predicting response and therapy control in patients with metastatic pancreatic cancer undergoing first-line therapy. Front Oncol 2013 0.83
119 Extravasations of oxaliplatin. J Clin Oncol 2003 0.83
120 Empirical antimicrobial monotherapy in patients after high-dose chemotherapy and autologous stem cell transplantation: a randomised, multicentre trial. Br J Haematol 2005 0.82
121 IkappaBalpha is required for marginal zone B cell lineage development. Eur J Immunol 2008 0.81
122 Adenovirus-mediated gene transfer of P16INK4/CDKN2 into bax-negative colon cancer cells induces apoptosis and tumor regression in vivo. Cancer Gene Ther 2002 0.81
123 Arsenic trioxide induces regulated, death receptor-independent cell death through a Bcl-2-controlled pathway. Oncogene 2005 0.81
124 BAY 43-9006/Sorafenib blocks CSF1R activity and induces apoptosis in various classical Hodgkin lymphoma cell lines. Br J Haematol 2011 0.81
125 Allogeneic partially HLA-matched dendritic cells pulsed with autologous tumor cell lysate as a vaccine in metastatic renal cell cancer: a clinical phase I/II study. Hum Vaccin Immunother 2013 0.80
126 Simultaneous cytokine analysis by cytometric bead array for the detection of leukaemia-reactive T cells in patients with chronic myeloid leukaemia. Br J Haematol 2006 0.80
127 Sorafenib, but not sunitinib, induces regulatory T cells in the peripheral blood of patients with metastatic renal cell carcinoma. Anticancer Drugs 2012 0.80
128 Oxaliplatin and 5-fluorouracil for heavily pretreated metastatic breast cancer: a preliminary phase II study. Anticancer Drugs 2003 0.80
129 The molecular biology of diffuse large B-cell lymphoma. Ther Adv Hematol 2011 0.79
130 Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after Upfront chemotherapy: the role of single-agent rituximab. Transplantation 2007 0.79
131 Differential expression of SHP-1 in chronic myeloid leukemia. Leuk Lymphoma 2014 0.79
132 Cytogenetic risk grouping by the monosomal karyotype classification is superior in predicting the outcome of acute myeloid leukemia undergoing allogeneic stem cell transplantation in complete remission. Eur J Haematol 2013 0.78
133 Intraoperative fresh-frozen plasma versus human albumin in craniofacial surgery--a pilot study comparing coagulation profiles in infants younger than 12 months. Thromb Haemost 2007 0.78
134 Cetuximab: appraisal of a novel drug against colorectal cancer. Recent Results Cancer Res 2007 0.78
135 Impairment of circulating myeloid dendritic cells in immunosuppressed renal/pancreas transplant recipients. Transplantation 2006 0.77
136 JAK2 V617F allele burden quantified by real time quantitative polymerase chain reaction and competitive polymerase chain reaction in patients with chronic myeloproliferative neoplasia. Leuk Lymphoma 2013 0.77
137 Reduced intensity conditioning prior to allogeneic stem cell transplantation in first complete remission is effective in patients with acute myeloid leukemia and an intermediate-risk karyotype. Int J Hematol 2010 0.77
138 Systematic genetic dissection of p14ARF-mediated mitochondrial cell death signaling reveals a key role for p21CDKN1 and the BH3-only protein Puma/bbc3. J Mol Med (Berl) 2010 0.77
139 Flow cytometric maturity score as a novel prognostic parameter in patients with acute myeloid leukemia. Ann Hematol 2015 0.77
140 Nilotinib for the treatment of chronic myeloid leukemia. Expert Rev Hematol 2008 0.77
141 Second-Line Treatment in Pancreatic Cancer Patients: Who Profits?-Results From the CONKO Study Group. Pancreas 2016 0.77
142 Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial. BMC Cancer 2014 0.77
143 Necrotic death but not irradiation abolishes costimulation of T-cell effector functions and survival by CD80-expressing tumor cells. Int J Cancer 2005 0.77
144 High prevalence of immunoglobulin light chain gene aberrations as revealed by FISH in multiple myeloma and MGUS. Genes Chromosomes Cancer 2014 0.77
145 Gene expression profiling of peripheral blood mononuclear cells during treatment with a gene-modified allogeneic tumor cell vaccine in advanced renal cell cancer: tumor-induced immunosuppression and a possible role for NF-κB. Int J Cancer 2014 0.77
146 BCR-ABL positive cells and chronic myeloid leukemia in immune suppressed organ transplant recipients. Eur J Haematol 2009 0.77
147 Anti-leukemia T cells in AML: TNF-α⁺ CD8⁺ T cells may escape detection and possibly reflect a stage of functional impairment. Hum Vaccin Immunother 2013 0.76
148 Downregulation of genes involved in DNA repair and differential expression of transcription regulators and phosphatases precede IgM-induced apoptosis in the Burkitt's lymphoma cell line BL60-2. Biochim Biophys Acta 2004 0.76
149 Extracorporeal photopheresis in graft-versus-host disease: ultraviolet radiation mediates T cell senescence in vivo. Transplantation 2004 0.76
150 Effects of Jak2 type 1 inhibitors NVP-BSK805 and NVP-BVB808 on Jak2 mutation-positive and Bcr-Abl-positive cell lines. Acta Haematol 2014 0.76
151 T cell recognition of bcr/abl in healthy donors and in patients with chronic myeloid leukaemia. Br J Haematol 2004 0.76
152 First-line treatment of pancreatic cancer patients with the combination of 5-fluorouracil/folinic acid plus gemcitabine: a multicenter phase II trial by the CONKO-study group. Cancer Chemother Pharmacol 2011 0.76
153 Identification of a chemokine receptor profile characteristic for mediastinal large B-cell lymphoma. Int J Cancer 2009 0.76
154 Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia. Leuk Lymphoma 2015 0.76
155 CD52 is not a promising immunotherapy target for most patients with multiple myeloma. Int J Hematol 2005 0.76
156 Adjuvant chemotherapy with folinic acid and 5-fluorouracil in patients with locally advanced rectal cancer previously treated by preoperative radiochemotherapy and curative tumor resection. Int J Colorectal Dis 2006 0.75
157 Interventionally implanted port catheter systems for hepatic arterial infusion of chemotherapy in patients with primary liver cancer: a phase II-study (NCT00356161). BMC Gastroenterol 2013 0.75
158 Eukaryotic initiation factor 2alpha phosphorylation is required for B-cell maturation and function in mice. Haematologica 2011 0.75
159 Sequencing of NUMB transcripts in chronic myeloid leukemia detects two single nucleotide polymorphisms. Leuk Lymphoma 2012 0.75
160 Impact of early remission by induction therapy on allogeneic stem cell transplantation for acute myeloid leukemia with an intermediate-risk karyotype in first complete remission. Eur J Haematol 2014 0.75
161 Acute hypokalemic tetraparesis induced by intravenous methotrexate. J Clin Oncol 2003 0.75
162 The use of microarray technologies in mantle cell lymphoma. Semin Hematol 2011 0.75
163 Long-term follow-up of patients with Philadelphia chromosome-positive chronic myeloid leukemia after stem cell mobilization under imatinib. Leuk Lymphoma 2010 0.75
164 Post-transplantation chronic myeloid leukemia. Clin Adv Hematol Oncol 2011 0.75
165 [Flow-cytometric immunophenotyping in clinical diagnostics]. Dtsch Med Wochenschr 2016 0.75
166 Longitudinal Study to Assess the Clinical Significance of MSI2 Expression in Chronic Myeloid Leukemia Patients. Acta Haematol 2016 0.75
167 [Therapy of Zenker's diverticulum]. Med Klin (Munich) 2002 0.75
168 Role of EBAG9 protein in coat protein complex I-dependent glycoprotein maturation and secretion processes in tumor cells. FASEB J 2010 0.75
169 Hepatic arterial infusion chemotherapy for liver metastases from gastric cancer: an analysis in Western patients. Tumori 2011 0.75
170 Granulocyte macrophage-colony stimulating factor plus interleukin-2 plus alpha-interferon plus 5-fluorouracil in the treatment of metastatic renal cell cancer: induction of CD80/86+ T cells indicates adverse outcome. J Immunother 2009 0.75
171 Effective use of high-dose chemotherapy and autologous stem cell rescue for relapsed adult Wilms' tumor and a novel alteration in intron 1 of the WT1 gene. J Pediatr Hematol Oncol 2004 0.75
172 Safety and efficacy of stem cell mobilization under imatinib therapy. Haematologica 2003 0.75
173 Quantitative RT-PCR of Wilms tumor gene transcripts (WT1) for the molecular monitoring of patients with accelerated phase bcr/abl + CML. Leuk Res 2005 0.75